The Association for the Accreditation of Human Research Protection Programs Inc
. (AAHRPP) today announced that it has awarded accreditation to five more organizations, including the first institution in Latin America.
The latest accreditations are yet another example of AAHRPP’s continued expansion and influence in the United States and emerging markets. The newly accredited organizations are:
Latin American countries are playing an increased role in clinical research. Mexico, in particular, is emerging as a leading clinical research location because of its proximity to the United States. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán is one of 12 National Institutes of Health in Mexico and is the among the country’s largest centers for medical training and research.
According to AAHRPP President and CEO Marjorie Speers, Ph.D., AAHRPP’s continued outreach worldwide reflects a longstanding commitment to protect participants and advance quality research both within and beyond the U.S.
“From the beginning, we recognized the global nature of the research enterprise,” Speers said. “We knew that accrediting U.S. institutions was critical and that it would be the first step toward a more ambitious goal of achieving one standard worldwide—for research quality and protections.”
To earn AAHRPP accreditation, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiránhad to demonstrate compliance with both Mexico’s requirements for research protections and U.S. regulations.
The four new U.S. accreditations reflect widespread acknowledgement that AAHRPP accreditation is the mark of a high-quality research protection program.
“Organizations of every size and sector of the research enterprise see the value of AAHRPP accreditation—the emphasis on quality and protections and the resulting respect of sponsors and peers,” Speers says.
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Mexico, Singapore and Taiwan.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.